

DAPAgliflozine to Attenuate Cardiac Remodeling after aCuTe myocardial Infarction

NCT05764057

Status	RECRUITING
Phase	Phase 3
Sponsor	Assistance Publique - Hôpitaux de Paris
Enrollment	450 participants

Key Eligibility Criteria

Inclusion (6)

- Age \geq 18 years;
- STEMI (e.g., ST elevation above the J-point of \geq 0.1 millivolt in two contiguous leads or left bundle branch block) or very high-risk NSTEMI (e.g., dynamic ECG changes or ongoing chest pain or acute heart failure or hemodynamic instability independent of ECG changes or life-threatening ventricular arrhythmias) with LV dysfunction (LVEF \leq 45%); after completion of PCI or angiography procedure
- eGFR \geq 25 mL/Min per 1.73m²;
- Systolic blood pressure (SBP) before first dosing \leq 100 mmHg and/or Diastolic blood pressure (DBP) \leq 70 mmHg before first dosing;
- Ability to provide written informed consent and willing to participate in the 6-month follow-up period.

... and 1 more (see full listing online)

Exclusion (15)

- Cardiogenic shock (SBP $<$ 90 mmHg with clinical signs of low output or patients requiring inotropic agents) at randomization;
- Referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture);
- Any other form of diabetes than diabetes type 2
- History of diabetic ketoacidosis (DKA); Known contra-indication to SGLT-2 inhibitors (hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption);
- \geq 1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea;

... and 10 more (see full listing online)

Locations (1 total)

Department of Cardiology AP-HP Hôpital européen Georges - Pompidou, Paris, France